AXL-IN-13
AXL-IN-13 is a potent, orally bioavailable small molecule inhibitor of AXL kinase, demonstrating high affinity with a Kd of 0.26 nM. It exhibits anticancer activity by reversing TGF-β1-induced epithelial-mesenchymal transition (EMT), thereby inhibiting cancer cell migration and invasion in vitro, and shows potential for in vivo tumor growth suppression studies.
Product Specifications
CAS Number
2376928-82-2
Product Name Alternative
FLT3, PDGFR, AXL, Smad, TGFb, TGF-b/Smad, TGFβ1, TGF-β/Smad, TGFβ, TGFbeta, TGF-beta, TGFbeta/Smad, TAMReceptor, TAM Receptor
Field of Research
Cardiovascular Research, Signal Transduction, Stem Cell & Developmental Biology
Purity
99.20% (May vary between batches)
Solubility
DMSO:6.33 mg/mL (10 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.58 mM)
Smiles
O (C=1C2=C (C=C (OCCCN3CCOCC3) C (OC) =C2) N=CC1) C4=C (F) C=C (NC=5C (C (NC6CCCCC6) =O) =CN (C) N5) C=C4
Molecular Formula
C34H41FN6O5
Molecular Weight
632.72
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Paxip1 sgRNA CRISPR Lentivector (Mouse) (Target 3)
TRAF2, CT (TNF Receptor-associated Factor 2, Tumor Necrosis Factor Type 2 Receptor-associated Protein 3, TRAP3) (Azide free) (HRP)
TRAF2, CT (TNF Receptor-associated Factor 2, Tumor Necrosis Factor Type 2 Receptor-associated Protein 3, TRAP3) (Azide free) (HRP)